TB-500 Research for Anti-Fibrosis

Thymosin beta-4 demonstrates anti-fibrotic effects across multiple organ systems in preclinical studies. Italian researchers showed reduced lung fibrosis in bleomycin-induced models (Conte et al., 2013), with a later study linking the effect to fewer IL-17-producing cells and lower IL-17 expression in the lung (Conte et al., 2014). Chinese research on liver fibrosis showed attenuation of hepatic stellate cell activation, with Tb4 downregulating the TGF-beta/Smad and PDGF/PDGFR pathways in a cholestatic liver fibrosis model (Chen et al., 2019). The mechanism appears to involve modulation of inflammatory and fibrotic signaling pathways. These anti-fibrotic effects remain preclinical. No human trials have specifically evaluated TB-500 or thymosin beta-4 for fibrotic conditions.